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Case Report
A 17-month-old female was brought to the emergency
department following a one-minute generalized tonic-
clonic seizure. In the emergency department, the patient
had 6 additional generalized tonic-clonic seizures and was
treated with lorazepam and phenobarbital. She had a head
computed tomography scan, complete blood count, lum-
bar puncture, and blood chemistries, all of which were
normal. Physical and neurological exam revealed coma,
normally reactive pupils, and ankle clonus. Head circum-
ference was normal (25% percentile).
The patient remained comatose for 5 days. She had no
further seizures during the hospitalization. An electroen-
cephalogram (EEG) obtained 2 days after admission
showed high amplitude, polymorphic delta and theta
activity, with irregular periods of relative attenuation, but
no epileptiform features. Her hospitalization was compli-
cated by fevers and hyponatremia, both of which were
resolved. Brain magnetic resonance imaging (MRI) stud-
ies (including with contrast) were performed on hospital
days 2 and 9; no abnormalities were noted. Because of
the unexplained coma, history of seizures and develop-
mental delay, and fevers, an extensive laboratory evaluation
was performed, including studies for infectious, endocrine,
metabolic, and genetic causes of her encephalopathy
(Table 1). A repeat EEG 8 days later consisted of high-
amplitude delta activity most prominent over the poste-
rior regions, poorly formed sleep spindles during sleep,
and no epileptiform features.
At the time of discharge (11 days following admis-
sion), the patient had no verbal output, did not follow any
commands, would not reach for objects or hold them, and
Cerebral folate deficiency syndrome is a rare butpotentially treatable cause of developmental delayand seizures. Although other disorders have been
associated with low cerebrospinal fluid (CSF) levels of
folate (such as Rett syndrome, Aicardi-Goutieres
syndrome, and some mitochondrial disorders),1-5 cerebral
folate deficiency syndrome is notable for the presence
of autoantibodies against membrane-associated folate
receptors of the choroid plexus. The blocking antibodies
prevent uptake of folate across the blood-spinal fluid bar-
rier.6 Importantly, successful treatment of cerebral folate
deficiency syndrome has been reported using high-dose
folinic acid.2,6,7
We report a child with a history of seizures and devel-
opmental delay who presented with seizures followed by a
prolonged episode of coma lasting 5 days. After extensive
testing, the diagnosis of cerebral folate deficiency syn-
drome was established. Despite treatment with folinic
acid, the patient developed intractable epilepsy and pro-
found developmental delay.
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had to be fed by her parents. However, she was visually
attentive and would track objects and could smile or
laugh interactively with her parents.
The patient’s medical history was significant for gener-
alized tonic-clonic seizures starting at the age of 5 months
for which she was treated with phenobarbital (which was
stopped by her parents at the age of 12 months).
Evaluation at the age of 6 months was normal, including
a routine EEG, head computed tomography scan, and
brain MRI. Family history, pregnancy and birth history,
and other medical history were unremarkable. There was
no known consanguinity. She had 2 older healthy siblings.
In addition, the patient had a history of mild develop-
mental delay; she did not begin to cruise along furniture
until the age of 15 months and was not walking independ-
ently at the time of admission. Although she babbled, she
was not saying any specific words at the time of admission,
and her parents felt that her receptive language skills were
delayed compared with other children her age.
Cerebrospinal fluid neurotransmitter analysis (for
biogenic monoamine metabolites, pterins, and 5-methyl-
tetrahydrofolate) was also done during her hospitaliza-
tion, and results (obtained after discharge) revealed low
levels of 5-methyltetrahydrofolate (28 nmol/L, normal =
40-187 nmol/L). Testing for folate receptor autoantibod-
ies in the serum was subsequently performed and
showed elevated levels (1.95 pmol folate receptor
blocked per mL serum, normal = 0). She was then
started on folinic acid replacement at a dose of 5 mg bid
(1 mg/kg/day).
Over the next 2 years, the patient developed intractable
seizures that were resistant to 5 different antiepileptic drugs,
both singly and in combinations (including gabapentin, lev-
etiracetam, lorazepam, oxcarbazepine, phenobarbital,
phenytoin, and topiramate), and placement of a vagal
nerve stimulator. Her seizures included a mixture of par-
tial complex, absence, tonic, and tonic-clonic seizures.
She had no recovery of her developmental milestones and
had continued deterioration in her neurological status.
Repeat cerebrospinal fluid 5-methyltetrahydrofolate lev-
els were normal (91 nmol/L) while on folinic acid. The
patient remained on folinic acid treatment for 6 months
and had her dose increased to 2 mg/kg/day before the par-
ents discontinued it. During this time, she had 3 admis-
sions for status epilepticus. Repeat EEGs showed
bitemporal sharp waves with seizures arising from the left
temporal or temporal-occipital regions with secondary
generalization (Figure 1A). A brain MRI at the age of 2
years was notable only because of mild cerebellar atrophy
(Figure 1B). Magnetic resonance spectroscopy showed
decreased N-acetylaspartate levels, likely due to loss of
neurons. She also required a Nissan and gastrostomy tube
placement because of bulbar dysfunction.
The patient’s most recent neurological exam at the age
of 3 years showed a severe static encephalopathy and nor-
mal head circumference (25th percentile). She has limb
spasticity, positive Babinski signs, and axial hypotonia.
Her current seizure frequency is >30 seizures/day. The
patient functions at the level of a 2-month-old and does
not visually track.
Table 1. List of Testing Which Yielded Normal Results
General Infectious Metabolic/Genetic
CBC with differential Blood culture Lactate
Chemistry 10 panel Urine culture Ammonia
AST, ALT, bilirubin CSF culture Serum very-long chain fatty acids
ESR, CRP Chest X ray Carnitine profile
CSF (glucose, protein, cell count) ASO, anti-DNase B Ceruloplasmin
TSH, free T4 HSV PCR (CSF) Uric acid
ANA HHV6 PCR (CSF) Urine organic acids
Lead EBV PCR (CSF) Serum amino acids
Homocysteine Enterovirus PCR (CSF) Urine amino acids
Vitamin B12 Mycoplasma PCR (CSF) CSF amino acids
Antimicrosomal antibody Mycoplasma IgG/IgM CSF lactate
Antithyroglobulin antibody Toxoplasma IgG/IgM Leukocyte lysosomal enzymes
Cortisol Varicella IgG/IgM Biotinidase
CSF AFB culture Methyltetrahydrofolate reductase
HIV1/2 antibodies Rett syndrome (methylation studies)
Arbovirus panel (IgG/IgM for California Palmitoyl-protein thioesterase I
equine virus, St Louis encephalitis, Tripeptidyl-peptidase I
Eastern equine encephalitis, Western
equine encephalitis)
NOTE: AST = aspartate aminotransferase; ALT = alanine transaminase; ASO = antistreptolysin O; ANA = antinuclear antibody; AFB = acid-fast bacilli; CSF = cerebrospinal
fluid; CRP = C-reactive protein; CBC = complete blood count; ESR = erythrocyte sedimentation rate; EBV = Epstein-Barr virus; TSH = thyroid stimulating hormone; HSV =
herpes simplex virus; HHV = human herpesvirus; HIV = human immunodeficiency virus; PCR = polymerase chain reaction.
 at Universite de Liege on January 26, 2012jcn.sagepub.comDownloaded from 
This study was reviewed and a waiver granted by the
University of Utah Institutional Review Board.
Discussion
This report describes a child with a progressive
encephalopathy and intractable epilepsy. The patient did
have a preceding history of mild developmental delay and
prior seizures, but her presentation was remarkable for
her prolonged unexplained coma. Despite extensive inves-
tigations during her initial admission, no explanation for
her seizures or coma was found until the results of her
cerebrospinal fluid neurotransmitter analysis returned.
The patient was diagnosed with cerebral folate
deficiency syndrome based on low cerebrospinal fluid levels
of 5-methyltetrahydrofolate, the central nervous system
metabolite of folate, and the presence of autoantibodies in
the blood against folate receptors. Folate is actively trans-
ported from the blood to the cerebrospinal fluid and brain by
folate receptors, and the antibodies presumably inhibit trans-
port of folate, leading to decreased cerebrospinal fluid levels.
Cerebral folate deficiency syndrome has been reported
in 30 patients.2,7,8 Typical symptoms include irritability,
developmental delay or regression, hypotonia and ataxia,
seizures, and dyskinesias.6 Magnetic resonance imaging
findings are variable between patients. Cerebellar atrophy
has been reported in 3 of 20 patients with cerebral folate
deficiency syndrome2 although cerebellar symptoms are
reported in nearly all patients. In some patients, no MRI
changes were noted,2,7,8 whereas in other cases, moderate
demyelination or supratentorial or infratentorial atrophy
was found.2
The etiology of cerebral folate deficiency syndrome is
unknown, and it is unknown whether it is primarily
genetic or is autoimmune with an interaction with envi-
ronmental triggers. Some support for the latter hypothe-
sis has been shown by a reduction in the titer of folate
receptor autoantibodies by adoption of a milk-free diet.9
Marked responses to treatment with folinic acid have
been reported,2,6-8 and it has been suggested that starting
treatment at an earlier age may be associated with an
improved response.2 Treatment with immunomodulatory
agents has not been reported.
This case underlines the importance of cerebrospinal
fluid neurotransmitter analysis in cases of unexplained
coma, intractable epilepsy, or episodic progressive devel-
opmental regression. Correct and timely diagnosis is
important because of the potentially treatable nature of
this disorder.6-8 Starting folinic acid therapy immediately
at diagnosis may be necessary to prevent irreversible cen-
tral nervous system sequelae. Unfortunately, our case
suggests that folinic acid treatment, even when started
early, may not be an adequate treatment for all patients.
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Figure 1. (A) Routine electroencephalogram obtained at the age of 3
years, bipolar montage. The pattern in the boxed region and underline
are part of the same discharge, consisting of left hemisphere 3-4 Hz spike
and wave discharges maximal in the temporal-occipital region. (B) Brain
magnetic resonance imaging, sagittal view, T1 series. Mild cerebellar
atrophy is seen (arrows).
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